A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Study ID
NCT06901336
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • [14C]-STX-478 — DRUG
    oral administration

Study Details

The main purpose of this study is to conduct blood tests to measure how much STX-478 is in the bloodstream and how the body handles and eliminates it in healthy participants. This study will involve a single dose of 14C radiolabeled STX-478. This means that a radioactive tracer substance, C14, will be incorporated into the study drug STX-478 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of STX-478.

Key Dates

First listed
Mar 28, 2025
Start date
Mar 20, 2025
Status verified
May 2025
Primary completion
May 6, 2025
Completion
May 6, 2025

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: [14C]-STX-478
    Healthy participants will receive a single dose of \[14C\]-STX-478.

Primary Outcome Measure

Percentage of the Total Radioactive Dose in Urinary, Fecal, and Urinary and Fecal Combined Excretion [ Time Frame: Baseline, Up to Day 29 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Pharmaron Clinical Pharmacology Center IncBaltimoreMaryland42374-

Find similar trials in Baltimore, MD

By research site
Pharmaron Clinical Pharmacology Center Inc· Baltimore, MD

Related Studies